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6Decisions will be made, with or without the
model.
Keeping this fact ﬁrmly in focus, the ISPOR Task
Force on Good Research Practices in Modeling
Studies [1] has produced a welcome and needed
addition to the numerous guidelines and checklists
that already abound in our ﬁeld. In a nutshell,
models should aim to aid decision makers—not to
prove or disprove cost-effectiveness for all time or
in all situations. It is generally better to base deci-
sions on imperfect data synthesized in transparent
and reasonable models than on no information at
all. The good practice principles detailed by this
Task Force, under the leadership of its chair Pro-
fessor Milton Weinstein, provide sound guidance to
the producers and users of modeling studies. And,
from the perspective of one who produces economic
models directly or indirectly (working with consul-
tants) to inform and inﬂuence decision makers—the
principles strike just the right balance between 
sensible practice and scientiﬁc rigor, while wisely
avoiding the more contentious issues of sponsorship
and bias. Although the aim here was clearly to
produce general principles, the authors also provide
some useful hints and tips along the way, thereby
advancing the state of the art.
This contribution comes from one of four Good
Research Practices Task Forces established by
ISPOR. Their aim is scientiﬁc—to promote “good
practice in health outcomes research and its use in
decision making” and “to provide guidance to the
researcher.” The overlapping missions of the four
Task Forces—on modeling studies, prospective
studies, retrospective database studies, and quality-
of-life outcomes assessment—were recognized from
the outset. This task force has clearly met its aim,
identifying good current practice while maintaining
a focus on the scientiﬁc aspects of modeling.
When it comes to decision-analytic modeling, the
message here is be transparent, be reasonable, be
practical, and be ﬂexible. Of these, transparency is
probably the most important because shortcomings
are likely and errors are possible. With trans-
parency, the users of models have a much better
chance of understanding intuitively the key factors
and variables in a model and of identifying and
understanding the limitations. The need for and
value of transparency is widely recognized and is
cited in many other guidelines.
How do these principles differ from other guide-
lines and checklists that have been produced? As
one who has struggled to deﬁne the term “model,”
we should all be grateful for their useful deﬁnition
of a health-care evaluation model:
An analytic methodology that accounts for
events over time and across populations, that is
based on data drawn from primary and/or sec-
ondary sources, and whose purpose is to estimate
the effects of an intervention on valued health
consequences and costs.
Compared with other statements written by com-
mittees, they have clearly hit a home run. Indeed,
the entire document is well written and clear.
One aspect of their approach that stands out is
the emphasis on the “expected value of informa-
tion” and its role in evaluating the reasonable
bounds of models. The principles laid out here rec-
ognize the costs of gathering and assembling infor-
mation in a way that has generally not been
reﬂected in most pharmacoeconomic guidelines 
and checklists. The reality is that we in industry are
increasingly asked by payers to justify prices, reim-
bursement, and formulary access at launch. For
reasons of cost and incentives to reach the market
quickly, our randomized clinical trials (RCTs) for
licensing are limited in size to demonstrate clinical
efﬁcacy and a reasonable risk-beneﬁt trade-off
between this efﬁcacy beneﬁt and safety. Even the
major deﬁnitive RCTs are not necessarily powered
to detect clinically signiﬁcant safety differences, and
also generally, they are underpowered to detect
resource use differences, especially those owing to
safety differences. Regulatory authorities recognize
(implicitly, if not explicitly) that it would be unwise
to limit access to many new drugs until all side
effects are fully known. It is a reasonable approach
to gather this information through postmarketing
surveillance. This reveals at least an intuitive under-
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standing by regulators of the value of information
principle. A decision can be made conditional on
the information available at the time and then mod-
iﬁed or even reversed in light of additional infor-
mation, as recent drug withdrawals from the
market illustrate. Pricing and reimbursement deci-
sions for drugs also increasingly seem to be subject
to a kind of conditional approval. If it is not rea-
sonable to make the ﬁnal deﬁnitive assessment of
product safety at launch, is it reasonable to make 
a once-and-for-all decision on reimbursement and
funding? These principles underscore the point that
model conclusions are, at best, conditional on the
input data.
The Gold et al. [2] volume ﬁrst enunciated the
useful “rule of reason” criterion in this ﬁeld: “Any
cost or outcome that is not appreciable in the
context of the analysis need not be included in 
the analysis.” In other words, if it will not affect the
analysis, do not worry about collecting any addi-
tional information on it. (This reminds one of the
comment on perfectionism often attributed to
Warren Buffett: “If something is not worth doing,
it’s not worth doing well.”) The value of informa-
tion criterion cited by the Task Force in several
places is a kind of generalization of this, but with
an interesting and new twist: “A case should be
made that reasonable opportunities to obtain new
additional data prior to modeling have been con-
sidered.” Being sensible, the Task Force says that it
is sufﬁcient to give a “heuristic argument.” This is
a valuable and new suggestion, to my knowledge,
that reviewers should apply in evaluating the
models they receive. It should not be too burden-
some or costly for model developers to comment on
this explicitly.
Another underappreciated feature of modeling
noted by the Task Force is: “Data availability may
affect choices regarding model structure.” They
provide a useful example in the area of disease
staging, where it might be better to not use a supe-
rior prognostic index in the model if more data are
available for the somewhat inferior predictor. This
observation also pertains to the tendency of some
modelers to begin by describing a detailed, exhaus-
tive pathway of clinical consequences for which
there are no data to make the estimates (and, more
frequently in the past, to use expert panels to esti-
mate everything). Clearly, these kinds of models 
are difﬁcult to estimate and validate. Well-meaning
modeling novices, especially those with a mostly
clinical orientation, have a natural tendency to head
off initially in this direction. Heeding the wisdom
of the Task Force will, hopefully, prevent some of
them from making this common error. At an early
stage, modeling is an art, as some practical judg-
ment about the trade-off between clinical realism
and economic signiﬁcance comes into play.
At a practical level, the Task Force provides some
useful advice and tips, but, more importantly, they
differ from other guidelines in their clear recogni-
tion of some of the constraints that we face and
their practical implications. First, they do not nec-
essarily assume that the latest techniques should
become the standard. For example, there is still lots
of room for deterministic models and sensitivity
analyses despite the growing usefulness of ﬁrst- and
second-order Monte Carlo simulations and the like.
The Task Force also rightly emphasizes the need for
cross-validation and corroboration. Too frequently,
we can be faulted for not attempting to interpret the
results of our model in relation to existing models
in the literature. Also, their suggested use of more
“structural sensitivity analyses” is a good one in this
context: how sensitive are the results to different
structural models—not just alternative parameter
estimates?
As thoughtful as this document is, it is not just
broad philosophy: there are also some useful state-
ments on the best current practice in several tech-
nical areas. For example, under data modeling there
are 10 tips on issues that beginners almost immedi-
ately encounter but about which they might have
trouble ﬁnding clear guidance in the literature, such
as using on-treatment data for effectiveness mea-
surement, using life tables for all-cause mortality,
combining domain-speciﬁc utilities into multiat-
tribute utility, and adjusting for inﬂation in alter-
native ways. Useful tips in other areas are that
memory should not be ignored in health state tran-
sitions and that it is reasonable to use expert con-
sensus methods in certain situations.
Although this Task Force and the other three
Good Practice Task Forces are focusing on the sci-
entiﬁc aspects of these issues, it should be clear that
their proposals might have important policy impli-
cations. At this stage, it is certainly safe to say that
modeling is an accepted fact of life in our ﬁeld and
that its inevitability and usefulness seems to be
widely recognized by public and private payers.
Although the evidence on the impact of Section 114
of the FDA Modernization Act of 1997 is not yet
in, managed care formulary committees are increas-
ingly requesting the kinds of evidence synthesized
in the types of models consistent with these 
principles.
It is important to recognize that the key princi-
ple of transparency can provide some measure of
8 Garrison
protection against the bad effects of bias and error,
but it is clearly not a perfect solution. One person’s
weighted average is another person’s black box: in
other words, models do not have to be mathemati-
cally sophisticated to be hard to follow. The wide-
spread emphasis on the systematic review and
summarization of the clinical evidence is well
founded. The clinical evidence is generally the
driver in these models, and understanding its
strength is essential for intuitively grasping the
robustness of the model.
From a purely personal perspective, after 10
years of working in industry, I do not have the sense
that the researchers in our shops or the consultants
we work with will to go to any extreme to get a
favorable result. Admittedly, the incentives are there
to produce what one might call the “best plausible
case” (or to be silent if the case is not strong). But
plausibility is deﬁned within the scientiﬁc standards
and methods that the vast majority of us attempt to
follow. By better deﬁning and improving those stan-
dards, the Task Force will help all of us to build
better models, so that decision makers can make
better decisions. (As an aside, it is worth mention-
ing that we are users as well as producers of models:
these same economic models support strategic
product development decisions from the earliest
stage—when only a target product proﬁle is avail-
able—through launch. Clearly, we ﬁnd them sufﬁ-
ciently reliable to be helpful to support major
investment decisions.)
Mark Pauly [3] stated years ago “. . . as long as
efforts are compensated, bias cannot be avoided.”
He also noted that some systems for dealing with
this reality might be better than others. Trans-
parency, adherence to professional standards and
guidance, peer review, skeptical buyers, and market
forces may actually provide a reasonable level pro-
tection. Decisions will be made: are we better off
with limited and potentially biased information or
no information?
One important policy question that the value of
information question raises is: are we doing enough
(as a society—or as a developed world) to gather
the information and build the models to address the
health-care resource allocation questions we face?
Information is a public good, and the private
market provision alone would tend to undersupply
the optimal amount, other things being equal.
Michael Drummond [4] has recently suggested that
we should consider raising the standards for the
clinical evidence that underlies our models—using
more head-to-head trials and longer follow-up. This
certainly deserves more discussion and analysis. But
those of us in the pharmaceutical industry, some-
times wonder if the considerable amount of scru-
tiny and analysis focused on new drugs is truly
efﬁcient—when older products and practices are
seldom reviewed. We all know that incentives
matter, but also we are already working in a
“second-best world” where the signals we receive
are not always clear and well structured. It is really
very difﬁcult to demonstrate that we are spending
too little or too much on these evaluations at this
time given the distortions to incentives that are
embedded in our health-care ﬁnancing and delivery
systems. Nonetheless, public payers around the
world and now private payers in the United States
are requesting more evaluations (and modeling). It
appears that this trend will continue.
As the Task Force emphasizes, these principles
are not written in stone and there are no last words
on these matters. Likewise, there are many other
related issues that deserve further exploration:
sponsorship and bias, incentives to invest in infor-
mation gathering, the role the “fourth hurdle,” and
so on. All in all, Professor Weinstein and his col-
leagues on the Task Force should be commended
and thanked graciously for their substantial contri-
bution and service to ISPOR and to all of us
working in this ﬁeld.
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